图卡替尼 API

Mechanism of Action

Tucatinib is a small molecule tyrosine kinase inhibitor (TKI) that works by blocking the activity of specific protein kinases involved in cancer cell proliferation and survival.

Tucatinib is a small molecule tyrosine kinase inhibitor (TKI) that works by blocking the activity of specific Tucatinib specifically targets the HER2 (human epidermal growth factor receptor 2) protein, which is often over-expressed in certain types of breast and gastric cancers. By blocking the activity of HER2, tucatinib inhibits the signaling pathways that drive cancer cell growth and survival, leading to cancer cell death.

Tucatinib has been approved by the US Food and Drug Administration (FDA) for the treatment of advanced HER2-positive breast cancer in combination with capecitabine and trastuzumab.

Indication

Tucatinib is a small molecule inhibitor of the HER2 protein and is indicated for the treatment of certain types of cancer. Specifically, it is approved for the treatment of advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine for adult patients who have received one or more prior anti-HER2-based regimens.

Tucatinib has shown to significantly improve progression-free survival compared to treatment with trastuzumab and capecitabine alone in clinical trials. However, it is important to note that the safety and effectiveness of tucatinib may vary depending on individual circumstances and that patients should consult their healthcare provider to determine if tucatinib is appropriate for their treatment.